Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)

OBJECTIVES: The objective of COAST-Y was to evaluate the effect of continuing versus withdrawing ixekizumab (IXE) in patients with axial spondyloarthritis (axSpA) who had achieved remission. METHODS: COAST-Y is an ongoing, phase III, long-term extension study that included a double-blind, placebo (P...

Descripción completa

Detalles Bibliográficos
Autores principales: Landewé, Robert BM, Gensler, Lianne S, Poddubnyy, Denis, Rahman, Proton, Hojnik, Maja, Li, Xiaoqi, Liu Leage, Soyi, Adams, David, Carlier, Hilde, Van den Bosch, Filip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292566/
https://www.ncbi.nlm.nih.gov/pubmed/33958326
http://dx.doi.org/10.1136/annrheumdis-2020-219717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292566/
https://www.ncbi.nlm.nih.gov/pubmed/33958326
http://dx.doi.org/10.1136/annrheumdis-2020-219717

Ejemplares similares